Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by barcodewhizon Jun 08, 2005 4:59pm
232 Views
Post# 9134246

Hemosol / ARC

Hemosol / ARC The ARC news you guys are talking about has been out for months. The original agreement that HML had with the ARC was that the ARC would provide 500,000 litres of Plasma to HML. However, the supply was contingent on HML doing specific fractionation and supplying the value components back to the ARC. In effect, HML was basically a paid agent. Despite it all sounding good...this is not necessarilly what HML wanted. In my opinion, HML is taking a far smarter and strategic path. Because of the simple fact that the Cascade process Yields and purtiy are so superior to the Cohn process, HML will be able to pay a PREMIUM to Plasma suppliers if they have to, they have a total competitive advantage. Supply will no be a problem. More importantly, when they source their own plasma and arent handcuffed by an "agency" deal like the ARC had suggested, they can turn around and make the big $$ by reselling the various valuable components that are in such high demand all over the world as opposed to simply taking a fixed cut. Because of the signficant yield /purity advantage, they will have pricing power on the fractionated products and will be in a very enviable position. You talk to the industry players, they realize the magnitude of whats going on here despite the fact that the capital markets are still penalizing HML and PLI. Ultimately , the value will win out for patient investors despite the real ugliness of manipulation we're seeing now. I still maintain we are very close to , if not at a LONG TERM bottom on this stock.
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse